Custom Medical Pen Injector Supplier for Drug Delivery 2026

Understanding the Growing Demand for Pen Injector Solutions

The rising incidence of chronic diseases such as diabetes and growth hormone deficiency has intensified the need for precision dosing and self-administration solutions. Healthcare systems face mounting pressure to reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. These pain points have driven pharmaceutical companies to seek partners capable of delivering reliable, customizable, and compliant drug-device combinations. Wuxi NEST Biotechnology Co., Ltd., operating under the brand name NEST, addresses these challenges as a one-stop provider of pharmaceutical packaging materials and drug delivery technologies, with a specific focus on injection and inhalation methods.

A Company Built on Integrated Manufacturing

Founded in 2018 with a strategic entry into the pharmaceutical packaging sector, NEST has developed a full in-house industry chain that spans independent mold design, research and development, automated mass production, and global logistics. This vertical integration allows the company to maintain consistency across every stage of production rather than relying on fragmented supply chains. Headquartered in Wuxi, Jiangsu, China, NEST has extended its footprint to the United States (Woodbridge, NJ and Phoenix, AZ), the Netherlands (Hendrik-Ido-Ambacht), the United Arab Emirates (Sharjah), Japan (Yokohama), and Turkey (Istanbul), positioning itself to serve pharmaceutical manufacturers across multiple regions.

Behind this global presence is a substantial operational infrastructure: 10,600 square meters of Class 100,000 cleanrooms, 3,600 square meters of Class 10,000 cleanrooms, and a dedicated 2,300 square meter pen injector workshop. A 76-person specialized quality team and a 50-person mold maintenance team support ongoing production consistency, reflecting the scale required to serve pharmaceutical clients with strict regulatory expectations.

Why Custom Manufacturing Matters in Injectable Drug Delivery

For pharmaceutical companies developing insulin, GLP-1, or FSH therapies, the choice of a pen injector supplier is rarely a one-size-fits-all decision. Dosing requirements, patient populations, and regulatory pathways differ across markets, which is why custom manufacturing capability is central to NEST’s value proposition. The company offers Freedom to Operate (FTO) analysis across major global markets—including China, the United States, the United Kingdom, and Europe—to help clients mitigate patent risks before committing to a device design. This type of early-stage support addresses a practical concern for manufacturers: avoiding costly intellectual property conflicts during product development.

Injection Pen Line: Addressing Diverse Clinical Needs

NEST’s Injection Pen Line is designed for self-administration in chronic disease management, including diabetes and growth hormone deficiency. The product portfolio includes several distinct configurations:

The Disposable Pen Injector is a three-step liquid medicine injection device developed to address the high cost of reusable devices and the risk of cross-contamination associated with them. It offers customization in both appearance and dosage—available in 36, 37, 50, 60, 74, 75, and 80 unit configurations—alongside professional data validation support for accuracy. The device provides visual and auditory feedback, with an injection start force of no more than 10 N for doses up to 60 IU.

The TSA Disposable Pen Injector is an internal-rotation type pen that avoids outward-extending components during dose adjustment, a design choice that limits the risk of accidental damage or contamination. It is manufactured under 100,000-class cleanroom conditions, and its mechanism prevents dosage from exceeding the remaining volume in the device.

The Prefilled Automatic Pen Injector Assembly (Two-Step) is a disposable, spring-driven auto-injection device intended to address needle anxiety and manual force limitations that patients may experience. It integrates a hidden needle for safety and an automatic locking shield that activates after injection to support compliance with safe disposal practices.

For long-term use cases, the Reusable Pen Injector supports replaceable cartridges and is built for a lifecycle exceeding 3,000 cycles. It accommodates both IU and mg scaling, offering flexibility for different therapeutic dosing requirements.

Primary Packaging: Materials Engineered for Sensitive Biologics

Beyond injection pens, NEST’s Primary Packaging Line supports the broader drug-device combination ecosystem. The RTU Cartridges are constructed from borosilicate glass and treated with a proprietary cross-linked siliconization technology that stabilizes gliding performance, an important factor for consistent dose delivery. These cartridges are available in 1.5 mL, 2.0 mL, and 3.0 mL formats.

For biologics that are sensitive to protein adsorption, the COP/COC Prefillable Vial, marketed as AccureVial®, offers a high-quality alternative to traditional borosilicate glass. Its low protein adsorption properties help preserve the stability of sensitive formulations, while the shatter-resistant COP material improves durability during handling and transport. The vial maintains performance across a temperature range of -196°C to 121°C, which is relevant for biologics requiring cryogenic storage or terminal sterilization.

Quality Systems and Regulatory Recognition

Trust in a pen injector supplier depends heavily on demonstrable quality systems and regulatory recognition. NEST has secured a broad set of certifications, including ISO 9001, ISO 13485, ISO 11137, ISO 15378, IATF 16949, CE MDR Certification, and MDSAP Five-Country Certification covering the USA, Canada, Australia, Japan, and Brazil. On the regulatory front, the company holds US FDA 510(k) clearances (K240961, K240774), US DMF filings (No. 40744, No. 42439, No. 40922), Canada Medical Device Licenses (No. 113733, No. 112619), and a China Class II Medical Device Certificate. These credentials, verified in part through TÜV SÜD assessments for ISO 9001, 13485, and 11137, provide pharmaceutical partners with a documented basis for regulatory due diligence.

On the technical side, NEST applies 100% multi-angle CCD camera inspection during production and maintains moist heat sterilization capabilities achieving a Sterility Assurance Level of 10⁻⁶. The company has also been identified as a provider of the first moist heat sterilized cartridges in China, a distinction relevant to manufacturers evaluating sterilization methods for injectable packaging.

A Service Model Built Around Full Lifecycle Support

NEST’s approach extends beyond manufacturing individual components. Its service model encompasses R&D, production, pre-sterilization, and customized assembly under a one-stop framework. This includes pre-sales customization, technical validation, automated assembly line planning, and global logistics support. With integrated warehousing across the US, Europe, and Asia, the company aims to shorten lead times for clients operating in multiple markets. Full lifecycle validation and batch traceability, supported by batch numbers and retained samples, further reinforce compliance with regulations such as RoHS and REACH.

Positioning for Global Drug-Device Combination Development

NEST has also engaged in partnerships with global pharmaceutical companies for final device assembly and drug-device combination validation, reflecting an ecosystem approach rather than a purely transactional supplier relationship. This is illustrated in practical application through a case involving a lyophilized live attenuated influenza vaccine, where NEST’s Disposable Intranasal Atomization Device was used for intranasal vaccination and successfully supported stimulation of a triple immune response across mucosal, humoral, and cellular pathways.

For pharmaceutical companies, research institutions, and hospitals evaluating a custom manufacturer for injectable drug delivery, the combination of in-house mold design, documented regulatory certifications, cleanroom-scale production, and global logistics infrastructure positions Wuxi NEST Biotechnology Co., Ltd. as a company built to support the full spectrum of pen injector and primary packaging needs, from early-stage FTO analysis through to global distribution.

https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.